KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Dynavax Technologies (DVAX) over the last 15 years, with Q4 2024 value amounting to $925000.0.

  • Dynavax Technologies' Gains from Investment Securities changed N/A to $925000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $925000.0, marking a year-over-year decrease of 3262.93%. This contributed to the annual value of $925000.0 for FY2024, which is 9085.97% down from last year.
  • Dynavax Technologies' Gains from Investment Securities amounted to $925000.0 in Q4 2024.
  • Over the past 5 years, Dynavax Technologies' Gains from Investment Securities peaked at $11.3 million during Q2 2024, and registered a low of -$21.2 million during Q3 2020.
  • For the 5-year period, Dynavax Technologies' Gains from Investment Securities averaged around $3.9 million, with its median value being $9.3 million (2020).
  • In the last 5 years, Dynavax Technologies' Gains from Investment Securities tumbled by 248439.96% in 2020 and then skyrocketed by 69605.77% in 2023.
  • Dynavax Technologies' Gains from Investment Securities (Quarter) stood at -$21.2 million in 2020, then grew by 9.52% to -$19.2 million in 2021, then skyrocketed by 101.94% to $373000.0 in 2022, then surged by 2690.35% to $10.4 million in 2023, then plummeted by 91.11% to $925000.0 in 2024.
  • Its Gains from Investment Securities stands at $925000.0 for Q4 2024, versus $11.3 million for Q2 2024 and $11.3 million for Q1 2024.